LJ-2698 is an adenosine A3 receptor antagonist under investigation for treating emphysema and DKD (Diabetic Kidney Disease). In mouse lung models, LJ-2698 effectively mitigates elastase-induced adverse effects and inhibits matrix metalloproteinase activity and apoptosis. Additionally, it is being explored for its potential in treating diabetic nephropathy, successfully preventing various types of kidney damage in mice.
Molecular Weight:
412.29
CAS Number:
[945457-84-1]
Formula:
C16H15Cl2N5O2S
T202459
* VAT and and shipping costs not included. Errors and price changes excepted
